Royalty Pharma Q3 Portfolio Receipts up 11%, guidance raised
Overview
Royalty Pharma Q3 2025 Portfolio Receipts grow 11% yr/yr to $814 mln
Adjusted EBITDA for Q3 2025 beats analyst expectations
Company raises full-year 2025 guidance for Portfolio Receipts to $3.2-$3.25 bln
Outlook
Royalty Pharma raises 2025 Portfolio Receipts guidance to $3,200 mln-$3,250 mln
Company expects 2025 Portfolio Receipts growth of 14% to 16%
Royalty Pharma sees negligible FX impact on 2025 Portfolio Receipts
Result Drivers
ROYALTY RECEIPTS GROWTH - Driven by strong performance of Voranigo, Tremfya, and cystic fibrosis franchise
CAPITAL DEPLOYMENT - Expanded portfolio with acquisitions including Imdelltra and Amvuttra
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Adjusted EBITDA | Beat | $779 mln | $695.81 mln (4 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Royalty Pharma PLC is $42.50, about 11% above its November 4 closing price of $37.84
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago
Press Release: ID:nGNX8cFqQg
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
Related Articles
Silver Frenzy Returns: Gold-Silver Ratio Falls Below 50 for First Time in 14 Years — Why Is Goldman Going Long?
TradingKey - Spot silver prices broke through the $90/oz mark this week, while the gold-to-silver ratio—a key indicator measuring their relative value—briefly fell below 50, hitting a 14-year low.
Microsoft Stock Outlook 2026: Why MSFT Remains the Most Balanced Magnificent Seven Bet
TradingKey - When investors get a look at 2026, there are not many large-cap technology names that cause as much discussion as Microsoft.
Cardano Price Prediction: When Will ADA Price Rise and Can It Reach $10 by 2030?
In early 2026, Cardano rebounded from its lows, with ADA trading at approximately $0.41, a gain of over 24% in seven days. Short-term resistance levels for ADA are set at $1 and $1.3, with any breakout contingent on ecosystem growth, macroeconomic factors, and Bitcoin's performance. Reaching $10 wit
European Central Bank 2026 Monetary Policy Outlook And Euro Exchange Rate 2026 Trend How?
TradingKey - The Federal Reserve has initiated an interest rate cut cycle, implementing its third consecutive rate cut since September this year, while the European Central Bank (ECB) has maintained a wait-and-see approach, keeping interest rates unchanged at 2.15% since July this year. In 2026, the Federal Reserve will maintain an accommodative monetary policy. If the European Central Bank maintains its current stance, what will be the future direction of the Euro exchange rate?
Gold Price Steady Climb and the Sudden Surge of Silver and Copper: Will Their Bull Run Extend Into 2026?
Dow Jones Market Data shows this marks the first time since 1980all three metals—gold, silver, and copper—simultaneously refreshed their all-time highs in the same year. Will this rally extend into 2026?
